Table 1.
Patient characterization at randomization and antidiabetic drug usage data at 4 months for patients with a history of diabetes
| Patient characteristics at randomization | Placebo | Ranolazine |
|---|---|---|
| n | 770 | 707 |
| Age (years) [median (25th to 75th percentile)] | 64 (57–71)* | 65 (57–72)* |
| Female sex (%) | 39.6* | 43.2* |
| Weight (kg/m2) [median (25th to 75th percentile)] | 85 (75–96)* | 84 (74–95)* |
| BMI (kg/m2) [median (25th to 75th percentile)] | 30 (27–33)* | 30 (27–33)* |
| Hypertension (%) | 84.4* | 84.5* |
| Hyperlipidemia (%) | 73.8* | 75.9* |
| Current smoker (%) | 19.5* | 17.4* |
| Antidiabetes drug usage [% (n)] | ||
| Sulfonylurea | 39.4 (303) | 42.9 (303) |
| Biguanide (metformin) | 37.4 (288) | 36.4 (257) |
| Insulin | 28.2 (217) | 27.3 (193) |
| Thiazolidinedione | 5.5 (42) | 4.2 (30) |
| α-Glucosidase inhibitor | 2.9 (22) | 3.0 (21) |
| Meglitinide | 2.3 (18) | 1.4 (10) |
| No antidiabetic drug | 16.6 (128) | 19.0 (134) |
| Monotherapy | 50.0 (385) | 47.4 (335) |
| Dual therapy | 28.3 (218) | 28.9 (204) |
| Three or more drugs | 5.0 (38) | 4.8 (34) |
*Patient characterization data are reproduced from Morrow et al. (16).